Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, two-arm, non-randomized, open-label, multicenter study evaluating the
safety and efficacy of 2 VELCADE-containing regimens. Patients will be treated with either a
combination of VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone
(VELCADE-R-CAP) or a combination of VELCADE, rituximab, cyclophosphamide, and prednisone
(VELCADE-R-CP) based on investigator preference. Following completion of the treatment
period, patients will receive maintenance therapy with rituximab up to a maximum of 2 years.